CYB004

{{Infobox drug

| drug_name =

| image =

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration = Inhalation, intravenous

| class = Serotonergic psychedelic; Serotonin receptor agonist

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = CYB-004; Deuterated dimethyltryptamine; Deuterated DMT; dDMT

| IUPAC_name =

| C= | H= | N= | O=

| SMILES =

| StdInChI =

| StdInChIKey =

}}

CYB004, or CYB-004, also known as deuterated dimethyltryptamine (dDMT), is a serotonergic psychedelic related to dimethyltryptamine (DMT) which is under development for the treatment of generalized anxiety disorder.{{cite web | title=CYB 004 | website=AdisInsight | date=14 August 2024 | url=https://adisinsight.springer.com/drugs/800062410 | access-date=28 October 2024}}{{cite web | title=Delving into the Latest Updates on Deuterated dtryptamine with Synapse | website=Synapse | date=27 October 2024 | url=https://synapse.patsnap.com/drug/8577e733c46648599fdd96ed1661ea3b | access-date=28 October 2024}}{{cite journal | vauthors = Peplow M | title = Next-generation psychedelics: should new agents skip the trip? | journal = Nature Biotechnology | volume = 42 | issue = 6 | pages = 827–830 | date = June 2024 | pmid = 38831049 | doi = 10.1038/s41587-024-02285-1 }}{{cite journal | vauthors = Varty G, Morgan M, Giardino O, Krakowsky J, Mueller T, Canal C, Pathare P, Avery K, Nivorozhkin A, Palfreyman M | title = ACNP 62nd Annual Meeting: Poster Abstracts P1 - P250: P80. Preclinical Characterization of CYB004: A Novel, Deuterated N,N-Dimethyltryptamine (DMT) Analog for the Potential Treatment of Generalized Anxiety Disorder (GAD) | journal = Neuropsychopharmacology | volume = 48 | issue = Suppl 1 | pages = 63–210 (109–110) | date = December 2023 | pmid = 38040809 | pmc = 10729595 | doi = 10.1038/s41386-023-01755-5 | publisher = Springer Science and Business Media LLC | doi-access = free }}{{cite journal | vauthors = Inamdar A, van der Heijden K, Nathan P, Reichelt A, Hegle A, Otto M, Pathare P, House-Gecewicz A, Bartlone A, Zuiker R, Giardino O, Varty G, Morgan M, Muhammad A, Krempien S, Avery K, Nivorozhkin A, Palfreyman M, Jacobs G | date = December 2023 | title = ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P425. Early Clinical Development of a Deuterated N,N-Dimethyltryptamine (DMT) Analog for the Treatment of Mental Health Conditions | journal = Neuropsychopharmacology | volume = 48 | issue = Suppl 1 | pages = 211–354 (310–311) | doi = 10.1038/s41386-023-01756-4 | pmid = 38040810 | pmc = 10729596 }} It is administered by inhalation or intravenous injection.

It is a tryptamine derivative and is a deuterated analogue and form of DMT. The pharmacodynamic profile of CYB004, including its interactions with serotonin receptors and its effects in animals, is similar to that of DMT. As with DMT, CYB004 is a potent agonist of the serotonin 5-HT_2A receptor and produces psychedelic-like effects in animals.{{cite journal | vauthors = Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B | title = Key Characteristics and Development of Psychoceuticals: A Review | journal = International Journal of Molecular Sciences | volume = 23 | issue = 24 | page = 15777 | date = December 2022 | pmid = 36555419 | pmc = 9779201 | doi = 10.3390/ijms232415777 | doi-access = free }} However, CYB004, due to its deuteration, is more resistant to metabolism than DMT and shows a longer elimination half-life (by 2.5- to 2.9-fold) and slower clearance (by 38 to 55%) in animals. The brain to plasma ratio of CYB004 was also increased (by 30%) relative to DMT, indicating slightly greater central permeability as well.

As of August 2024, CYB004 is in phase 2 clinical trials for generalized anxiety disorder. It was also under development for the treatment of substance-related disorders and of other psychiatric disorders, but development for these indications was discontinued. The drug is under development by Cybin. The exact chemical structure of CYB004 (i.e., which hydrogen atoms are deuterated) does not yet seem to have been disclosed. However, Cybin patented deuterated tryptamines, including deuterated forms of DMT like DMT-d₁₀, in 2023.{{cite patent | country = US | number = 2023/0357147 | title=Deuterated tryptamine derivatives and methods of use | inventor = Nivorozhkin A, Palfreyman M| assign = Cybin IRL Ltd. | url=https://patents.google.com/patent/US20230357147A1/en | pubdate = 8 October 2024 | quote = }} Other related drugs include the deuterated tryptamine CYB003 and the deuterated phenethylamines CYB005 and CYB210010.